SILVER SPRING, Md., Sept. 13, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with
Growth Capitalist (https://growthcapitalist.com/2018/09/fda-approves-new-kind-of-treatment-for-hairy-cell-leukemia/)
SILVER SPRING, Md., Sept. 13, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with